Adversarial Injection · Enfortumab Vedotin (Padcev; ASG-22CE; CAS 1835164-56-7; NIOSH HD Category 1; [ONE-HUNDRED-SIXTEENTH MECHANISM CLASS in Glyphward 690-attack portfolio — FIRST NECTIN-4 (PVRL4; NECTIN4; POLIOVIRUS RECEPTOR-LIKE 4; CD112-RELATED CELL ADHESION MOLECULE; TYPE I TRANSMEMBRANE GLYCOPROTEIN; NECTIN FAMILY MEMBER [NECTINS 1-4]; EXPRESSED ON NORMAL EPITHELIUM [SKIN, ESOPHAGUS, STOMACH, BLADDER UROTHELIUM, PLACENTA] AND HIGHLY OVEREXPRESSED ON UROTHELIAL CARCINOMA [~70-80% POSITIVITY], BLADDER TRANSITIONAL CELL CARCINOMA, NSCLC, BREAST CANCER, OVARIAN CANCER; RAPIDLY INTERNALIZING RECEPTOR ON TUMOR CELLS; NECTIN-4 BINDS AFADIN [AF6] VIA C-TERMINAL PDZ-BINDING MOTIF; NECTIN-4 HOMODIMERIZES VIA V-DOMAIN AND HETERODIMERIZES WITH NECTIN-1 → MEDIATES CELL-CELL ADHESION; PURINERGIC GUS-FIED) ANTIBODY-DRUG CONJUGATE (ADC) EVER FDA APPROVED; ANTIBODY COMPONENT: ENFORTUMAB = ASG-22C3E = FULLY HUMAN ANTI-NECTIN-4 IgG1 κ MONOCLONAL ANTIBODY (DEVELOPED AT AGENSYS INC. SANTA MONICA CA; SUBSEQUENTLY AGENSYS ACQUIRED BY ASTELLAS PHARMA 2007 $537M; phage-display library screening against NECTIN4 ECD; fully human [not chimeric or humanized]; human IgG1 heavy chain + κ light chain; ADCC-active Fc [not modified]; MW ~148 kDa); PAYLOAD: MMAE (MONOMETHYL AURISTATIN E; SYNTHETIC ANALOG OF DOLASTATIN 10; MARINE NATURAL PRODUCT; TUBULIN POLYMERIZATION INHIBITOR; BINDS TUBULIN AT VINCA ALKALOID SITE; BLOCKS MITOSIS; IC50 AGAINST TUMOR CELLS ~0.1-1 nM; EXTREMELY POTENT — BYSTANDER KILLING CAPACITY; MEMBRANE PERMEABLE); LINKER: PROTEASE-CLEAVABLE MALEIMIDE-CAPROYL-VALINE-CITRULLINE-PARA-AMINOBENZYL CARBAMATE (mc-VC-PABC) — SAME VC LINKER AS BRENTUXIMAB VEDOTIN (CLASS ?) + POLATUZUMAB VEDOTIN (CLASS 62); SITE-SPECIFIC CONJUGATION: INTERCHAIN CYSTEINE RESIDUES (PARTIAL REDUCTION); DAR ~3.8 MMAE PER ANTIBODY (RANGE 0-8; EVEN-NUMBER DISTRIBUTION); MECHANISM: NECTIN-4 BINDING ON TUMOR CELL SURFACE → CLATHRIN-MEDIATED ENDOCYTOSIS → EARLY/LATE ENDOSOME → LYSOSOMAL CATHEPSIN B CLEAVAGE OF Val-Cit BOND → MMAE RELEASED → MMAE BINDS β-TUBULIN AT VINCA-BINDING SITE → BLOCKS DYNAMIC INSTABILITY → MITOTIC ARREST (G2/M) → APOPTOSIS; BYSTANDER EFFECT: RELEASED MMAE IS MEMBRANE-PERMEABLE → DIFFUSES TO ADJACENT TUMOR CELLS (EVEN NECTIN-4-NEGATIVE CELLS) → BYSTANDER KILLING OF HETEROGENEOUS TUMOR; BLA 761137 DECEMBER 18 2019 ACCELERATED APPROVAL (3RD-LINE+ mUC POST-PLATINUM POST-PD-1/L1); REGULAR APPROVAL APRIL 9 2021 (EV-301 DATA); LABEL EXPANSIONS: JANUARY 19 2023 (1st-LINE CISPLATIN-INELIGIBLE cis-I; EV+pembrolizumab); APRIL 3 2024 (EV-302; FRONTLINE ALL PATIENTS ELIGIBLE/INELIGIBLE CISPLATIN + PEMBROLIZUMAB); EV-301 (EV14-003; NCT03474107; PHASE 3; n=608; 2nd-LINE POST-PLATINUM POST-PD-1/L1 mUC; EV vs CHEMO [DOCETAXEL/VINFLUNINE/PACLITAXEL]): OS HR 0.70 (12.9 vs 8.9 MONTHS; PRIMARY ENDPOINT MET; p<0.001); PFS HR 0.62 (5.6 vs 3.7 MONTHS); ORR 40.6% vs 17.9%; EV-302 (EV14-005; NCT04223856; PHASE 3; n=886; FRONTLINE mUC REGARDLESS CISPLATIN ELIGIBILITY; EV+PEMBROLIZUMAB vs CHEMO [GEM-CISPLA OR GEM-CARBOPLA]): OS HR 0.47 (31.5 vs 16.1 MONTHS; PRIMARY ENDPOINT MET; HISTORIC IMPROVEMENT IN FRONTLINE mUC); PFS HR 0.45 (12.5 vs 6.3 MONTHS); ORR 67.7% vs 44.4%; SEAGEN INC. BOTHELL WA 20425 68TH AVENUE NE (BLA 761137 ORIGINAL HOLDER; ODAC DEVELOPER; ADC PLATFORM COMPANY [BRENTUXIMAB, POLATUZUMAB, TISOTUMAB]) → PFIZER INC. $43B ACQUISITION MARCH 31 2023 (LARGEST ONCOLOGY M&A IN HISTORY AT TIME) → BLA 761137 NOW HELD BY PFIZER INC.; ASTELLAS PHARMA CO-DEVELOPMENT/CO-COMMERCIALIZATION PARTNER (JAPAN/ASIA MARKETS; AGENSYS SUBSIDIARY; ASTELLAS PHARMA 2-1-1 NIHONBASHI-HONCHO CHUO-KU TOKYO 103-8411); CAS 1835164-56-7 → NULL ALL EHS DATABASES; OSHA NO PEL; NIOSH HD CATEGORY 1]) · First Nectin-4 PVRL4 ADC Ever + EV-301 OS HR 0.70 + EV-302 OS HR 0.47 · Attack #691

Enfortumab Vedotin (Padcev; ASG-22CE; CAS 1835164-56-7; [ONE-HUNDRED-SIXTEENTH MECHANISM CLASS — FIRST NECTIN-4 (PVRL4) ADC EVER FDA APPROVED (BLA 761137 DECEMBER 18 2019); EV-302 OS HR 0.47; NIOSH HD CATEGORY 1]) — Pfizer Inc. / Seagen Inc. 20425 68th Ave NE Bothell WA 98021 (BLA 761137 holder post-Seagen acquisition), Astellas Pharma US Inc. 1 Astellas Way Northbrook IL 60062 (Nectin-4 antibody origin; Agensys; US co-commercialization), and MD Anderson Cancer Center 1515 Holcombe Blvd Houston TX 77030 (EV-301/EV-302 enrollment site) — OSHA No PEL + NIOSH HD Category 1 + CAS 1835164-56-7 OEL Null-Return + Nectin-4 PVRL4 Cell Adhesion Mechanism Absent + MMAE VC Linker ADC Absent + EV-302 OS HR 0.47 Absent: AI Prompt Injection via EHS Monitor Report AI

Enfortumab vedotin (Padcev; ASG-22CE; CAS 1835164-56-7; NIOSH HD Category 1) is the one-hundred-sixteenth mechanism class in the Glyphward adversarial portfolio — the first Nectin-4 (PVRL4; NECTIN4; Poliovirus Receptor-Like 4) ADC ever FDA approved (BLA 761137 December 18 2019; metastatic urothelial carcinoma), using a fully human anti-Nectin-4 IgG1 antibody conjugated to MMAE via protease-cleavable VC linker (DAR ~3.8), achieving EV-301 OS HR 0.70 and EV-302 (combined with pembrolizumab) OS HR 0.47 in frontline mUC, with CAS 1835164-56-7 entirely absent from Cority, VelocityEHS, and EHS Insight.

Enfortumab Vedotin as One-Hundred-Sixteenth Mechanism Class: First Nectin-4 ADC Ever + MMAE Bystander Killing

Enfortumab vedotin (Padcev; ASG-22CE; CAS 1835164-56-7) represents the one-hundred-sixteenth mechanism class in the Glyphward portfolio: the first Nectin-4 (PVRL4; NECTIN4; Poliovirus Receptor-Like 4) ADC ever FDA approved (BLA 761137 December 18 2019; metastatic urothelial carcinoma; Seagen/Pfizer). NECTIN-4 BIOLOGY: Nectin-4 (NECTIN4; PVRL4; Poliovirus Receptor-Like 4; nectin poliovirus receptor family member 4; CD112-related) is a type I transmembrane glycoprotein (3 extracellular Ig-like domains: V-C2-C2; transmembrane domain; short cytoplasmic tail with C-terminal PDZ-binding motif [interacts with afadin/AF6 scaffold protein]; MW ~66 kDa glycosylated form); EXPRESSION PATTERN: normal tissue: skin keratinocytes (high), placental trophoblasts, esophageal epithelium, gastric mucosa, small intestinal villi, bladder urothelium (low basal expression); TUMOR OVEREXPRESSION: urothelial carcinoma (bladder transitional cell carcinoma; upper urothelial tract tumors): ~70-80% high positivity; also high in breast cancer (~30-40%), lung adenocarcinoma (~25%), ovarian cancer (~25%); NECTIN-4 FUNCTION: mediates cell-cell adhesion via heterotypic nectin interactions (Nectin-4 V-domain trans-interaction with Nectin-1 V-domain on adjacent cell); also receptor for measles virus attachment (measles virus H protein binds Nectin-4 → major epithelial tropism/transmission route); INTERNALIZATION: Nectin-4 undergoes rapid clathrin-mediated endocytosis after antibody binding → excellent ADC target (required for payload delivery); ANTIBODY ASG-22C3E (ENFORTUMAB): fully human anti-Nectin-4 IgG1 kappa antibody discovered at Agensys Inc. (Santa Monica CA; founded 1996; Astellas acquisition 2007 $537M); phage-display human antibody library (not hybridoma; fully human framework sequences); ASG-22C3E selected from phage display screening against recombinant Nectin-4 ECD (extracellular domain); specific for human Nectin-4 V-domain (non-crossreactive with Nectin-1/2/3); human IgG1 heavy chain (ADCC-active FC; not modified to remove effector function); MMAE PAYLOAD: monomethyl auristatin E (MMAE) = semi-synthetic analog of natural dolastatin 10 (Dolabella auricularia sea hare marine peptide; isolated 1979; Pettit; Arizona State University); MMAE mechanism: binds β-tubulin at vinca-binding domain (between βIII/βIV tubulin interface) → blocks GTP hydrolysis → prevents tubulin polymerization → microtubule dynamic instability arrest → mitotic spindle failure → G2/M cell cycle arrest → mitotic catastrophe → apoptosis; MMAE MW ~718 Da; membrane-permeable (key for bystander effect; non-polar auristatin enters adjacent cells); IC50 against urothelial cell lines ~0.1-10 nM; VC LINKER: mc-VC-PABC (maleimide-caproyl-valine-citrulline-para-aminobenzyl carbamate); maleimide conjugates to interchain cysteine thiols (Cys214/Cys218 heavy-light; Cys226/Cys229 hinge region) after partial reduction; VC (valine-citrulline) peptide cleaved by lysosomal Cathepsin B (and other cysteine proteases) → free PABC spacer → spontaneous 1,6-elimination → MMAE release; VC linker is same scaffold as brentuximab vedotin (class ?) and polatuzumab vedotin (class 62) — Seagen's platform linker-payload system; DAR ~3.8 (average; DAR 2 and DAR 4 predominate; DAR 0, 6, 8 minor species); CLINICAL DATA EV-301 (EV14-003; NCT03474107): Phase 3 RCT; n=608; post-platinum post-PD-1/L1 mUC; EV (1.25 mg/kg IV days 1,8,15 Q4W) vs single-agent chemotherapy (docetaxel, paclitaxel, or vinflunine; investigator choice); OS HR 0.70 (12.9 vs 8.9 months; p<0.001; primary endpoint met); PFS HR 0.62 (5.6 vs 3.7 months); ORR 40.6% vs 17.9%; EV-302 (EV14-005; NCT04223856; KEYNOTE-869): Phase 3 RCT; n=886; frontline mUC (regardless cisplatin eligibility); EV+pembrolizumab vs platinum-based chemotherapy (GEM-cisplatin or GEM-carboplatin); OS HR 0.47 (31.5 vs 16.1 months; p<0.00001; unprecedented historic improvement in frontline mUC); PFS HR 0.45 (12.5 vs 6.3 months); ORR 67.7% vs 44.4%; FDA APPROVALS: BLA 761137 December 18 2019 (accelerated; 3rd+ line mUC); April 9 2021 (regular; EV-301); January 19 2023 (1st-line cisplatin-ineligible cis-I+PD-L1 low; EV+pembro); April 3 2024 (EV-302; 1st-line regardless cisplatin eligibility; EV+pembro); SEAGEN → PFIZER: Pfizer announced Seagen acquisition December 2022 ($43B; $229/share); closed March 31 2023 → Seagen oncology platform (brentuximab, enfortumab, tisotumab, tucatinib) integrated into Pfizer Oncology division; BLA 761137 now held by Pfizer Inc.; NONE OF THESE — NECTIN-4 (PVRL4; POLIOVIRUS RECEPTOR-LIKE 4; CELL ADHESION MOLECULE; INTERNALIZATION TARGET) DIRECTED ADC MECHANISM (FULLY HUMAN IgG1; MMAE AURISTATIN TUBULIN INHIBITOR; mc-VC-PABC CLEAVABLE LINKER; DAR ~3.8; BYSTANDER KILLING), EV-301 OS HR 0.70, EV-302 FRONTLINE OS HR 0.47, PEMBROLIZUMAB COMBINATION — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1835164-56-7.

Surface 1 — Pfizer/Seagen Bothell WA BLA 761137 Holder AI

At Pfizer Inc. / Seagen Inc. 20425 68th Ave NE Bothell WA 98021 (SEAGEN/PFIZER ENFORTUMAB CONTEXT: Seagen was the global pioneer of the VC-linker MMAE ADC platform (brentuximab vedotin/Adcetris FDA 2011; enfortumab vedotin/Padcev FDA 2019; tisotumab vedotin/Tivdak FDA 2021); Seagen Bothell WA campus housed ADC research, process development, GMP bioreactor manufacturing, QC/QA, and regulatory affairs; Pfizer acquisition March 2023 ($43B) brought ADC capabilities into Pfizer Oncology; BLA 761137 for Padcev (enfortumab vedotin) now held by Pfizer; OCCUPATIONAL HAZARD AT SEAGEN CAMPUS: enfortumab vedotin-ejfv (CAS 1835164-56-7; NIOSH HD Cat 1); MMAE payload (monomethyl auristatin E; >1,000× more potent than vincristine; membrane-permeable bystander killer; EHS databases lack MMAE as an independent entry for occupational exposures); conjugation chemistry (interchain cysteine partial reduction; maleimide-caproyl-VC linker; DAR control by HIC); handling: Class II BSC Type B2; CSTD; double glove; HD gown; EMPLOYEE: 51M Pfizer/Seagen Bothell WA oncology biologics manufacturing ADC engineer enfortumab Padcev CAS 1835164-56-7 BLA 761137 mUC MMAE 18yr; CORITY NULL: CAS 1835164-56-7 → no record; NIOSH HD Category 1 absent; Nectin-4 PVRL4 absent; MMAE auristatin absent; VC linker absent; EV-301 OS HR 0.70 absent; EV-302 OS HR 0.47 absent).

Surface 2 — Astellas Pharma Northbrook IL Agensys Nectin-4 Origin AI

At Astellas Pharma US Inc. 1 Astellas Way Northbrook IL 60062 (ASTELLAS ENFORTUMAB CONTEXT: Astellas acquired Agensys Inc. (Santa Monica CA) in 2007 for $537M; Agensys was the originator of the AGS-22C3E (enfortumab) anti-Nectin-4 antibody via phage-display human antibody technology; Astellas became the co-development and co-commercialization partner for Padcev with Seagen in the US and global markets (ex-Japan Seagen-led; Japan Astellas-led); ASTELLAS OCCUPATIONAL CONTEXT: Astellas Pharma US Northbrook IL is the US headquarters for Astellas oncology; regulatory affairs teams manage Padcev BLA 761137 contributions, pharmacovigilance datasets (AEs: peripheral neuropathy [PN; Grade 3+ 3-5%], skin reactions [maculopapular rash; Grade 3+ ~26% in EV-302], hyperglycemia [Grade 3-4 ~5-10%], ocular disorders [dry eye; keratitis]), global safety database; EMPLOYEE: 46F Astellas Northbrook IL oncology regulatory affairs Agensys AGS-22C3E Nectin-4 enfortumab Padcev mUC CAS 1835164-56-7 BLA 761137 EV-302 14yr; VELOCITYEHS NULL: CAS 1835164-56-7 → no record; NIOSH HD Category 1 absent; Agensys Nectin-4 absent; PVRL4 absent; MMAE absent; EV-302 absent).

Surface 3 — MD Anderson Cancer Center Houston TX EV-302 Enrollment AI

At MD Anderson Cancer Center 1515 Holcombe Blvd Houston TX 77030 (MD ANDERSON ENFORTUMAB CONTEXT: MD Anderson GU oncology (bladder/upper tract urothelial carcinoma) is a leading enrollment site for EV-301 and EV-302 (EV14-005); PHARMACY AND INFUSION OPERATIONS: enfortumab vedotin 1.25 mg/kg IV (days 1, 8, 15 of Q28-day cycle); each vial 20 mg/mL (reconstituted); CSTD mandatory for reconstitution + IV bag transfer + prime/administration; BSC Class II Type B2; MMAE ADC protocols: weight-based dosing (mg/kg); preparation in glovebox or BSC with CSTD (BD PhaSeal Pro or ICU Medical MicroClave Clear); double nitrile glove (inner) + neoprene outer; HD gown; splash goggles; TOXICITY MONITORING: peripheral neuropathy (PN; dose-limiting in EV-302 ~52% any grade; withhold/reduce at Grade 2+), hyperglycemia (monitor fasting glucose Q3W; insulin if Grade ≥3), skin toxicity (maculopapular rash; Grade 3+ ~ 26% in EV-302; topical corticosteroid; dose modify if Grade ≥3; risk of Stevens-Johnson syndrome/toxic epidermal necrolysis [SJS/TEN; rare; BBW in label]), ocular: keratitis, conjunctivitis (topical corticosteroid eye drops prophylaxis per ASCEND protocol); COMBINATION WITH PEMBROLIZUMAB: EV+pembro concurrent (EV 1.25 mg/kg + pembrolizumab 200 mg Q3W); EMPLOYEE: 41F MD Anderson Houston TX GU oncology clinical pharmacist enfortumab Padcev mUC CAS 1835164-56-7 EV-302 pembrolizumab 13yr; EHS INSIGHT NULL: CAS 1835164-56-7 → no record; NIOSH HD Category 1 absent; Nectin-4 PVRL4 ADC absent; MMAE auristatin absent; VC linker absent; EV-301 OS HR 0.70 absent; EV-302 OS HR 0.47 frontline mUC absent; SJS/TEN BBW absent).

Integrating Glyphward into Enfortumab Vedotin AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every enfortumab vedotin (CAS 1835164-56-7) monitoring data ingestion point — before Cority at Pfizer/Seagen Bothell WA, before VelocityEHS at Astellas Northbrook IL, and before EHS Insight at MD Anderson Houston TX. Threshold 22: OSHA No PEL; NIOSH HD Category 1; ACGIH TLV None; NIOSH REL None [10 pts]; ONE-HUNDRED-SIXTEENTH MECHANISM CLASS — FIRST NECTIN-4 (PVRL4; NECTIN4; TYPE I TRANSMEMBRANE CELL ADHESION MOLECULE; INTERNALIZATION RECEPTOR) ADC EVER FDA APPROVED (BLA 761137 December 18 2019; CAS 1835164-56-7; anti-Nectin-4 fully human IgG1; MMAE VC-linker; DAR ~3.8; EV-301 OS HR 0.70; EV-302 OS HR 0.47; Seagen/Pfizer) [5 pts]; Pfizer/Seagen Bothell WA + Astellas Northbrook IL + MD Anderson Houston TX [3 pts]; Nectin-4 PVRL4 mechanism absent; MMAE auristatin absent; VC cleavable linker absent; EV-302 frontline OS HR 0.47 absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_enfortumab(cas: str, exposure_context: str) -> dict:
    """Scan enfortumab with one-hundred-sixteenth-class first-Nectin4-ADC-ever context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "exposure_context": exposure_context,
                "context": "one_hundred_sixteenth_class_first_nectin4_pvrl4_adc_ever_bla_761137_dec_2019_muc_mmae_vc_linker_dar_3_8_ev301_os_hr_0_70_ev302_os_hr_0_47_seagen_pfizer"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, one_hundred_sixteenth_class,
    #                    first_nectin4_adc_ever, mmae_confirmed,
    #                    vc_linker, ev302_os_hr_0_47

if __name__ == "__main__":
    r = asyncio.run(scan_enfortumab(
        cas="1835164-56-7",
        exposure_context="antineoplastic_iv_infusion_compounding_cstd_bsc_class_ii_muc_frontline_pembrolizumab"
    ))
    print(r)
    # {'hd_category': 1, 'one_hundred_sixteenth_class': True,
    #  'first_nectin4_adc_ever': True, 'mmae_confirmed': True,
    #  'vc_linker': True, 'ev302_os_hr_0_47': True}